# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
Stifel analyst Stephen Willey maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $20 to $21.
-424B5
Zymeworks Inc. (NASDAQ:ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of n...
Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $0.07 by 80...
ZW191 is the Company's novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (A...
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106 ZYME: 13% | Zymeworks shares are trading higher after t...